Franck‐Emmanuel Nicolini

Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

Neil P. Shah, Valentín García‐Gutiérrez, Antonio Jiménez‐Velasco et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2019 · 150 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Cidofovir in the Treatment of BK Virus–Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation

Michaël Philippe, Florence Ranchon, Lila Gilis et al. · Biology of Blood and Marrow Transplantation · 2015 · 79 citations · Full text

Pharmacy, Hematology, Infectious Diseases +14

Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009

Marie‐Christine Nicolle, Thomas Bénet, A. Thiebaut et al. · Haematologica · 2011 · 75 citations · Full text

Medicine, Hematology, Infectious Diseases +13

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance

Catherine Roche‐Lestienne, Lauréline Deluche, Sélim Corm et al. · Blood · 2008 · 72 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

Jörge E. Cortes, Raghunadharao Digumarti, Purvish M. Parikh et al. · American Journal of Hematology · 2013 · 64 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11